Table 1.
Recipient baseline characteristics
| Parameters | Total (n = 91) |
|---|---|
| Variables recorded at the time of transplantation | |
| Age, years, median (IQR) | 42.4 (28.1–54.1) |
| Female sex, n (%) | 32 (35.2) |
| Underlying kidney disease, n (%) | |
| Glomerulonephritis | 39 (42.9) |
| Polycystic kidney disease | 18 (19.8) |
| Obstructive nephropathy | 11 (12.1) |
| Diabetic nephropathy | 3 (3.3) |
| Hypertensive nephropathy | 1 (1.1) |
| Other, unknown | 19 (20.9) |
| Preemptive transplantation, n (%) | 28 (30.8) |
| Recipient of a retransplant, n (%) | 10 (11) |
| ABO/HLA-incompatible transplantation, n (%)a | 10 (11) |
| Sum of HLA mismatch in A, B and DR, median (IQR) | 3 (2–4) |
| Baseline immunosuppression, n (%) | |
| Induction with IL-2R antibody | 82 (90.1) |
| Tacrolimus | 75 (82.4) |
| Trough level at 6 months, ng/ml, median (IQR) | 7.7 (6.0–9.1) |
| Trough level at 12 months, ng/ml, median (IQR) | 6.3 (5.2–8.0) |
| Cyclosporin A | 6 (6.6) |
| mTOR inhibitorb | 3 (3.3) |
| Belatacept | 6 (6.6) |
| Mycophenolic acid | 88 (96.7) |
| Azathioprine | 1 (1.1) |
| Steroid | 90 (98.9) |
IL-2R interleukin‑2 receptor, IQR interquartile range, mTOR mammalian target of rapamycin
aEight patients were transplanted across ABO and two patients across both ABO and HLA-donor-specific antibody (DSA) barriers
bSirolimus or everolimus